Meng-Ting Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meng-Ting Wang has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Chen-Liang Tsai
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.
10 shared publications Chen Wei Lin
Safeway Pharmacy, Lynden, Washington, WA, USA
7 shared publications- Yun-Han Wang
School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
7 shared publications Jun-Ting Liou
Division of Cardiology, Department of Internal medicine, China Medical University Hsinchu Hospital, Hsinchu, Taiwan
5 shared publicationsJyun-Heng Lai
College of Pharmacy, The University of Texas at Austin, Austin
4 shared publications- Jun-Ting Liou
Division of Cardiology China Medical University Hsinchu Hospital Zhubei City Taiwan
3 shared publications
Latest Publications
- 21 September 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (7) , e70184
Comparative Effectiveness of Lithium‐ Vs. Valproate‐Based Combinations With Atypical Antipsychotics in Preventing Rehospitalization After a First Manic Episode of Bipolar I Disorder
Background: Relapse after a first manic episode is common in bipolar I disorder and frequently leads to rehospitalization. Lithium and valproate, often prescribed with atypical antipsychotics, remain central to maintenance therapy; however, no randomized trials have directly compared these regimens in early‐course illness. This study compared lithium plus atypical antipsychotics (Li + AAPs) versus valproate plus atypical antipsychotics (Val + AAPs) for preventing bipolar‐related rehospitalizations after the first hospitalization for mania. Methods: This was a new‐user, propensity score–matched cohort study of patients discharged after their first hospitalization for acute mania, using Taiwan's National Health Insurance claims data (2011–2022). Patients initiating Li + AAPs or Val + AAPs within 30 days of discharge were followed for rehospitalization for any mood episode (manic, depressive, or mixed). Secondary outcomes included episode‐specific rehospitalization and annualized hospitalization rates. Results: Among 3,909 matched patients (1397 Li + AAP and 2,512 Val + AAP; mean [SD] age, 42.4 [14.2] years; 42.9% male), Li + AAPs were associated with a higher risk of rehospitalization for any mood episode compared to Val + AAPs (hazard ratio [HR], 1.18; 95% CI, 1.03–1.35), primarily driven by manic relapse (HR, 1.16; 95% CI, 1.01–1.35). No significant differences were observed for depressive or mixed episodes. The annual rehospitalization rate for any mood episodes was also higher with Li + AAPs (incidence rate ratio, 1.34; 95% CI, 1.17–1.54). Conclusions: In this nationwide cohort of patients with first‐episode mania, Val + AAPs were associated with a lower risk of bipolar rehospitalization compared to Li + AAPs, suggesting potential early‐phase maintenance advantages of valproate combinations over lithium combinations following first mania discharge.
- 21 September 2026
- Published by Wiley in Bipolar Disorders
- Vol. 28 (7) , e70184
Comparative Effectiveness of Lithium‐ Vs. Valproate‐Based Combinations With Atypical Antipsychotics in Preventing Rehospitalization After a First Manic Episode of Bipolar I Disorder
Background: Relapse after a first manic episode is common in bipolar I disorder and frequently leads to rehospitalization. Lithium and valproate, often prescribed with atypical antipsychotics, remain central to maintenance therapy; however, no randomized trials have directly compared these regimens in early‐course illness. This study compared lithium plus atypical antipsychotics (Li + AAPs) versus valproate plus atypical antipsychotics (Val + AAPs) for preventing bipolar‐related rehospitalizations after the first hospitalization for mania. Methods: This was a new‐user, propensity score–matched cohort study of patients discharged after their first hospitalization for acute mania, using Taiwan's National Health Insurance claims data (2011–2022). Patients initiating Li + AAPs or Val + AAPs within 30 days of discharge were followed for rehospitalization for any mood episode (manic, depressive, or mixed). Secondary outcomes included episode‐specific rehospitalization and annualized hospitalization rates. Results: Among 3,909 matched patients (1397 Li + AAP and 2,512 Val + AAP; mean [SD] age, 42.4 [14.2] years; 42.9% male), Li + AAPs were associated with a higher risk of rehospitalization for any mood episode compared to Val + AAPs (hazard ratio [HR], 1.18; 95% CI, 1.03–1.35), primarily driven by manic relapse (HR, 1.16; 95% CI, 1.01–1.35). No significant differences were observed for depressive or mixed episodes. The annual rehospitalization rate for any mood episodes was also higher with Li + AAPs (incidence rate ratio, 1.34; 95% CI, 1.17–1.54). Conclusions: In this nationwide cohort of patients with first‐episode mania, Val + AAPs were associated with a lower risk of bipolar rehospitalization compared to Li + AAPs, suggesting potential early‐phase maintenance advantages of valproate combinations over lithium combinations following first mania discharge.
- Open Access
- 29 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (12) , 7502-7513
Comparative cardiovascular risk of sulfonylureas with low‐ and high‐affinities for cardiac mitochondrial adenosine triphosphate‐sensitive potassium channels versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A cohort study
Aims: To individually evaluate the cardiovascular safety of low‐ and high‐affinity cardiac mitochondrial ATP‐sensitive potassium (mitoK ATP ) channel sulfonylureas by comparing each to dipeptidyl peptidase‐4 inhibitors (DPP‐4i), a generally cardiovascular‐neutral comparator, given prior evidence suggesting greater cardiovascular risk with high‐affinity agents and the absence of a neutral active comparator. Methods: A new user, active comparator cohort study using propensity score‐based inverse probability of treatment weighting was conducted with Taiwan's nationwide claims database (2012–2022). Patients with recent pre‐entry cardiovascular events were excluded. The primary outcome was 3‐point major adverse cardiovascular events (MACE: ischaemic stroke, myocardial infarction, cardiovascular death); secondary outcomes included each MACE component and all‐cause mortality. Results: The study cohort included 466 158, 83 031, and 473 539 new users of low‐affinity mitoK ATP ‐channel sulfonylureas (gliclazide, glimepiride), high‐affinity sulfonylureas (glyburide, glipizide), and DPP‐4i, respectively (mean age, 60.2 years; 55.6% male). Compared with DPP‐4i, low‐affinity sulfonylureas were not associated with increased risks of 3‐point MACE (Hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.96–1.06), cardiovascular death (HR, 1.01; 95% CI, 0.93–1.08), or all‐cause mortality (HR, 0.97; 95% CI, 0.93–1.01). Conversely, high‐affinity sulfonylureas were associated with 1.17–1.31‐fold increased risks of 3‐point MACE, cardiovascular death, and all‐cause mortality. Conclusions: Initiating low‐affinity mitoK ATP ‐channel sulfonylureas demonstrated cardiovascular safety comparable to DPP‐4i, whereas high‐affinity sulfonylureas were linked to increased cardiovascular risk and all‐cause mortality. These findings suggest low‐affinity sulfonylureas are a safer alternative to high‐affinity agents and as safe as DPP‐4i. They may be appropriate for individuals with diabetes when newer therapies are inaccessible or unnecessary.
- 29 September 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (12) , 7502-7513
Open AccessComparative cardiovascular risk of sulfonylureas with low‐ and high‐affinities for cardiac mitochondrial adenosine triphosphate‐sensitive potassium channels versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A cohort study
Aims: To individually evaluate the cardiovascular safety of low‐ and high‐affinity cardiac mitochondrial ATP‐sensitive potassium (mitoK ATP ) channel sulfonylureas by comparing each to dipeptidyl peptidase‐4 inhibitors (DPP‐4i), a generally cardiovascular‐neutral comparator, given prior evidence suggesting greater cardiovascular risk with high‐affinity agents and the absence of a neutral active comparator. Methods: A new user, active comparator cohort study using propensity score‐based inverse probability of treatment weighting was conducted with Taiwan's nationwide claims database (2012–2022). Patients with recent pre‐entry cardiovascular events were excluded. The primary outcome was 3‐point major adverse cardiovascular events (MACE: ischaemic stroke, myocardial infarction, cardiovascular death); secondary outcomes included each MACE component and all‐cause mortality. Results: The study cohort included 466 158, 83 031, and 473 539 new users of low‐affinity mitoK ATP ‐channel sulfonylureas (gliclazide, glimepiride), high‐affinity sulfonylureas (glyburide, glipizide), and DPP‐4i, respectively (mean age, 60.2 years; 55.6% male). Compared with DPP‐4i, low‐affinity sulfonylureas were not associated with increased risks of 3‐point MACE (Hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.96–1.06), cardiovascular death (HR, 1.01; 95% CI, 0.93–1.08), or all‐cause mortality (HR, 0.97; 95% CI, 0.93–1.01). Conversely, high‐affinity sulfonylureas were associated with 1.17–1.31‐fold increased risks of 3‐point MACE, cardiovascular death, and all‐cause mortality. Conclusions: Initiating low‐affinity mitoK ATP ‐channel sulfonylureas demonstrated cardiovascular safety comparable to DPP‐4i, whereas high‐affinity sulfonylureas were linked to increased cardiovascular risk and all‐cause mortality. These findings suggest low‐affinity sulfonylureas are a safer alternative to high‐affinity agents and as safe as DPP‐4i. They may be appropriate for individuals with diabetes when newer therapies are inaccessible or unnecessary.
- Open Access
- 3 July 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (3) , 214-227
Use of dipeptidyl peptidase‐4 inhibitors is associated with lower risk of severe renal outcomes in pre‐dialysis patients with Type 2 diabetes
Objectives: Patients with diabetes and Stage 5 chronic kidney disease (CKD) not on dialysis are susceptible to renal replacement therapy and severe complications. Among limited antidiabetic options in this vulnerable population, dipeptidyl peptidase‐4 (DPP‐4) inhibitors (DPP‐4i) are widely used; however, supporting evidence is scant. This study assessed severe renal outcomes associated with DPP‐4i in diabetic and pre‐dialysis patients. Methods: This study employed an active‐comparator and propensity score–based inverse probability of treatment weighting approach, using Taiwan's nationwide healthcare claims database from 2012 to 2020. We identified patients with diabetes and CKD stage 5 not on dialysis who received erythropoietin (erythropoietin‐stimulating agent), a drug reimbursed for patients with an estimated glomerular filtration rate 2 . The primary outcome was a composite of renal replacement therapy, renal death, and kidney‐related hospitalization events, and secondary outcomes included each component of the composite and hypoglycemia. Results: We included 7271 diabetic and pre‐dialysis patients with CKD stage 5, of whom 5028 received DPP‐4i and 2243 received meglitinides. DPP‐4i were associated with a 14% reduced risk of the renal composite outcome compared to meglitinides (weighted hazard ratio [HR], 0.86; 95% confidence interval, 0.81–0.92). Individual component analysis revealed that the decreased risk was confined to renal replacement therapy, with a 17% reduction. DPP‐4i was related to a 41% decreased severe hypoglycemia risk. Conclusions: In diabetic and pre‐dialysis patients with CKD stage 5, DPP‐4i are related to a lower risk of the renal composite outcome, primarily driven by lower renal dialysis risk, and a lower hypoglycemia risk compared with meglitinides.
- 3 July 2025
- Published by Wiley in Journal of Internal Medicine
- Vol. 298 (3) , 214-227
Open AccessUse of dipeptidyl peptidase‐4 inhibitors is associated with lower risk of severe renal outcomes in pre‐dialysis patients with Type 2 diabetes
Objectives: Patients with diabetes and Stage 5 chronic kidney disease (CKD) not on dialysis are susceptible to renal replacement therapy and severe complications. Among limited antidiabetic options in this vulnerable population, dipeptidyl peptidase‐4 (DPP‐4) inhibitors (DPP‐4i) are widely used; however, supporting evidence is scant. This study assessed severe renal outcomes associated with DPP‐4i in diabetic and pre‐dialysis patients. Methods: This study employed an active‐comparator and propensity score–based inverse probability of treatment weighting approach, using Taiwan's nationwide healthcare claims database from 2012 to 2020. We identified patients with diabetes and CKD stage 5 not on dialysis who received erythropoietin (erythropoietin‐stimulating agent), a drug reimbursed for patients with an estimated glomerular filtration rate 2 . The primary outcome was a composite of renal replacement therapy, renal death, and kidney‐related hospitalization events, and secondary outcomes included each component of the composite and hypoglycemia. Results: We included 7271 diabetic and pre‐dialysis patients with CKD stage 5, of whom 5028 received DPP‐4i and 2243 received meglitinides. DPP‐4i were associated with a 14% reduced risk of the renal composite outcome compared to meglitinides (weighted hazard ratio [HR], 0.86; 95% confidence interval, 0.81–0.92). Individual component analysis revealed that the decreased risk was confined to renal replacement therapy, with a 17% reduction. DPP‐4i was related to a 41% decreased severe hypoglycemia risk. Conclusions: In diabetic and pre‐dialysis patients with CKD stage 5, DPP‐4i are related to a lower risk of the renal composite outcome, primarily driven by lower renal dialysis risk, and a lower hypoglycemia risk compared with meglitinides.
- Open Access
- 10 April 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (4) , e70138
Dipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis
Introduction: Evidence on the safety of antidiabetic agents in end‐stage renal disease (ESRD) patients requiring dialysis, a group often excluded from randomized controlled trials, is scant. Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), widely used for type 2 diabetes mellitus (T2DM) management in this group, have raised concerns regarding the risk of heart failure (HF). However, real‐world evidence on HF risk with DPP‐4i in dialysis‐dependent diabetic patients is limited. We aimed to assess HF safety of DPP‐4i compared with sulfonylureas (SU)/meglitinides in a nationwide T2DM population with ESRD requiring dialysis.Methods: A new user, active comparator cohort study employing propensity score‐inverse probability of treatment weighting was conducted utilizing Taiwan's nationwide healthcare claims database (2012–2020). Evaluated outcomes included hospitalizations for HF or cardiovascular death as the primary outcome, with major adverse cardiovascular events (MACEs), all‐cause mortality, and severe hypoglycemia as secondary outcomes, using weighted Cox proportional hazards models.Results: The study included 6882 patients initiating DPP‐4i and 6174 starting SU/meglitinides, with a mean age of 66.4 years and 53.1% male. Initiation of DPP‐4i versus SU/meglitinide was not associated with increased risks of HF hospitalizations, cardiovascular death, MACEs, or all‐cause mortality, but was significantly tied to a 44% reduced risk of severe hypoglycemia.Conclusions: This study's findings indicate that in T2DM patients with ESRD requiring dialysis, DPP‐4i do not elevate the risk of hospitalizations for HF, cardiovascular death, or all‐cause mortality, but significantly lower the risk of severe hypoglycemia compared with SUs/meglitinides. This supports the preference for DPP‐4i over SUs or meglitinides for managing T2DM in dialysis patients.
- 10 April 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (4) , e70138
Open AccessDipeptidyl Peptidase‐4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus and End‐Stage Renal Disease Requiring Dialysis
Introduction: Evidence on the safety of antidiabetic agents in end‐stage renal disease (ESRD) patients requiring dialysis, a group often excluded from randomized controlled trials, is scant. Dipeptidyl peptidase‐4 inhibitors (DPP‐4i), widely used for type 2 diabetes mellitus (T2DM) management in this group, have raised concerns regarding the risk of heart failure (HF). However, real‐world evidence on HF risk with DPP‐4i in dialysis‐dependent diabetic patients is limited. We aimed to assess HF safety of DPP‐4i compared with sulfonylureas (SU)/meglitinides in a nationwide T2DM population with ESRD requiring dialysis.Methods: A new user, active comparator cohort study employing propensity score‐inverse probability of treatment weighting was conducted utilizing Taiwan's nationwide healthcare claims database (2012–2020). Evaluated outcomes included hospitalizations for HF or cardiovascular death as the primary outcome, with major adverse cardiovascular events (MACEs), all‐cause mortality, and severe hypoglycemia as secondary outcomes, using weighted Cox proportional hazards models.Results: The study included 6882 patients initiating DPP‐4i and 6174 starting SU/meglitinides, with a mean age of 66.4 years and 53.1% male. Initiation of DPP‐4i versus SU/meglitinide was not associated with increased risks of HF hospitalizations, cardiovascular death, MACEs, or all‐cause mortality, but was significantly tied to a 44% reduced risk of severe hypoglycemia.Conclusions: This study's findings indicate that in T2DM patients with ESRD requiring dialysis, DPP‐4i do not elevate the risk of hospitalizations for HF, cardiovascular death, or all‐cause mortality, but significantly lower the risk of severe hypoglycemia compared with SUs/meglitinides. This supports the preference for DPP‐4i over SUs or meglitinides for managing T2DM in dialysis patients.
Environmentally friendly inhaler regimens for COPD
Consider patient characteristics when making treatment decisions
Environmentally friendly inhaler regimens for COPD
Consider patient characteristics when making treatment decisions
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 18
Comparative effectiveness and safety of escalating to triple therapy versus switching to dual bronchodilators after discontinuing LABA/ICS in patients with COPD: a retrospective cohort study
Background: The latest guidelines discourage the use of long-acting beta2-agonists/inhaled corticosteroids (LABA/ICS) for chronic obstructive pulmonary disease (COPD). However, there is a lack of evidence regarding the optimal subsequent treatment after discontinuing LABA/ICS. Objectives: To compare the effectiveness and safety of switching from LABA/ICS to triple therapy (LABA/long-acting muscarinic antagonists (LAMA)/ICS) or to dual bronchodilators (LABA/LAMA) in COPD patients. Design: This was a new-user, active-comparator, and propensity score-matched cohort study analyzing the Taiwanese nationwide healthcare insurance claims. Methods: We recruited COPD patients switching from LABA/ICS to triple therapy or to dual bronchodilators from 2015 to 2019. The primary effectiveness outcome was the annual rate of exacerbations, and safety outcomes included severe pneumonia and all-cause mortality. Stratification by prior exacerbations was conducted. Results: After matching, each group comprised 1892 patients, 55% of whom experienced no exacerbations in the prior year. Treatment with LABA/LAMA/ICS versus LABA/LAMA showed comparable annual rate of moderate-to-severe exacerbations (incidence rate ratio, 1.04; 95% confidence interval (CI), 0.91–1.19). However, switching to LABA/LAMA/ICS was associated with increased risks of severe pneumonia (hazard ratio (HR), 1.65; 95% CI, 1.30–2.09) and all-cause death (HR, 1.39; 95% CI, 1.09–1.78). In patients with⩾2 prior exacerbations, LABA/LAMA/ICS versus LABA/LAMA was related to a 21% reduced rate of exacerbations but with a twofold increased pneumonia risk and a 49% elevated risk of all-cause mortality. Conclusion: Switching from LABA/ICS to triple therapy versus dual bronchodilators in COPD patients was associated with similar rates of annual exacerbations but was related to elevated risks of severe pneumonia and all-cause mortality. Among frequent exacerbators, triple therapy was associated with lower rates of exacerbation but was accompanied by increased risks of pneumonia and mortality compared to LABA/LAMA. Careful consideration of the examined safety events is necessary when switching from LABA/ICS to triple therapy in COPD management.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 18
Open AccessComparative effectiveness and safety of escalating to triple therapy versus switching to dual bronchodilators after discontinuing LABA/ICS in patients with COPD: a retrospective cohort study
Background: The latest guidelines discourage the use of long-acting beta2-agonists/inhaled corticosteroids (LABA/ICS) for chronic obstructive pulmonary disease (COPD). However, there is a lack of evidence regarding the optimal subsequent treatment after discontinuing LABA/ICS. Objectives: To compare the effectiveness and safety of switching from LABA/ICS to triple therapy (LABA/long-acting muscarinic antagonists (LAMA)/ICS) or to dual bronchodilators (LABA/LAMA) in COPD patients. Design: This was a new-user, active-comparator, and propensity score-matched cohort study analyzing the Taiwanese nationwide healthcare insurance claims. Methods: We recruited COPD patients switching from LABA/ICS to triple therapy or to dual bronchodilators from 2015 to 2019. The primary effectiveness outcome was the annual rate of exacerbations, and safety outcomes included severe pneumonia and all-cause mortality. Stratification by prior exacerbations was conducted. Results: After matching, each group comprised 1892 patients, 55% of whom experienced no exacerbations in the prior year. Treatment with LABA/LAMA/ICS versus LABA/LAMA showed comparable annual rate of moderate-to-severe exacerbations (incidence rate ratio, 1.04; 95% confidence interval (CI), 0.91–1.19). However, switching to LABA/LAMA/ICS was associated with increased risks of severe pneumonia (hazard ratio (HR), 1.65; 95% CI, 1.30–2.09) and all-cause death (HR, 1.39; 95% CI, 1.09–1.78). In patients with⩾2 prior exacerbations, LABA/LAMA/ICS versus LABA/LAMA was related to a 21% reduced rate of exacerbations but with a twofold increased pneumonia risk and a 49% elevated risk of all-cause mortality. Conclusion: Switching from LABA/ICS to triple therapy versus dual bronchodilators in COPD patients was associated with similar rates of annual exacerbations but was related to elevated risks of severe pneumonia and all-cause mortality. Among frequent exacerbators, triple therapy was associated with lower rates of exacerbation but was accompanied by increased risks of pneumonia and mortality compared to LABA/LAMA. Careful consideration of the examined safety events is necessary when switching from LABA/ICS to triple therapy in COPD management.
- Open Access
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (12) , e2245854
Comparison of Mitochondrial Adenosine Triphosphate–Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin
Importance: Sulfonylureas are frequently used as add-on to metformin in type 2 diabetes (T2D), and individual sulfonylurea agents carry different risks of cardiovascular disease. Sulfonylureas’ different affinities to cardiac mitochondrial adenosine triphosphate–sensitive potassium (mitoKATP) channels have been speculated to account for the intraclass difference in cardiovascular risk from in vitro and ex vivo studies; however, this hypothesis has not been assessed in a general population with diabetes receiving sulfonylureas added to metformin.Objective: To compare the risk of myocardial infarction (MI), ischemic stroke, or cardiovascular death in patients with T2D treated with mitoKATP channel high-affinity sulfonylureas and low-affinity sulfonylureas as add-on to metformin.Design, Setting, and Participants: This is a new-user, active-comparator, and propensity score–matched cohort study with analysis of the Taiwanese Diabetes Mellitus Health Database from 2006, to 2017. Data analysis was performed from August 2020 to July 2021.Exposures: Cardiac mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylureas combined with metformin.Main Outcomes and Measures: Primary outcome was major adverse cardiovascular events (MACEs), a composite of cardiovascular death or hospitalization for either MI or ischemic stroke. Secondary outcomes included individual MACE components, heart failure, arrhythmia, all-cause mortality, and severe hypoglycemia. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs).Results: Each sulfonylurea group comprised 53 714 patients (mean [SD] age, 54.7 [12.1] years; 31 962 men [59.5%]). MitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas when combined with metformin were associated with an increased risk of MACE (aHR, 1.18; 95% CI, 1.03-1.34), MI (aHR, 1.34; 95% CI, 1.04-1.73), all-cause mortality (aHR, 1.27; 95% CI, 1.03-1.57), and severe hypoglycemia (aHR, 1.82; 95% CI, 1.58-2.10), but not with increased risks of ischemic stroke, cardiovascular death, arrhythmia, and heart failure. The duration analyses revealed the highest MACE risk during 1 to 90 days after initiation of mitoKATP channel high-affinity sulfonylureas (aHR, 6.06; 95% CI, 4.86-7.55).Conclusions and Relevance: Use of mitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas was associated with an increased MACE risk in patients with T2D concomitantly receiving metformin, suggesting that high-affinity blockage of the mitoKATP channels could account for sulfonylurea-associated MACEs.
- 1 December 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (12) , e2245854
Open AccessComparison of Mitochondrial Adenosine Triphosphate–Sensitive Potassium Channel High- vs Low-Affinity Sulfonylureas and Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With Metformin
Importance: Sulfonylureas are frequently used as add-on to metformin in type 2 diabetes (T2D), and individual sulfonylurea agents carry different risks of cardiovascular disease. Sulfonylureas’ different affinities to cardiac mitochondrial adenosine triphosphate–sensitive potassium (mitoKATP) channels have been speculated to account for the intraclass difference in cardiovascular risk from in vitro and ex vivo studies; however, this hypothesis has not been assessed in a general population with diabetes receiving sulfonylureas added to metformin.Objective: To compare the risk of myocardial infarction (MI), ischemic stroke, or cardiovascular death in patients with T2D treated with mitoKATP channel high-affinity sulfonylureas and low-affinity sulfonylureas as add-on to metformin.Design, Setting, and Participants: This is a new-user, active-comparator, and propensity score–matched cohort study with analysis of the Taiwanese Diabetes Mellitus Health Database from 2006, to 2017. Data analysis was performed from August 2020 to July 2021.Exposures: Cardiac mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylureas combined with metformin.Main Outcomes and Measures: Primary outcome was major adverse cardiovascular events (MACEs), a composite of cardiovascular death or hospitalization for either MI or ischemic stroke. Secondary outcomes included individual MACE components, heart failure, arrhythmia, all-cause mortality, and severe hypoglycemia. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs).Results: Each sulfonylurea group comprised 53 714 patients (mean [SD] age, 54.7 [12.1] years; 31 962 men [59.5%]). MitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas when combined with metformin were associated with an increased risk of MACE (aHR, 1.18; 95% CI, 1.03-1.34), MI (aHR, 1.34; 95% CI, 1.04-1.73), all-cause mortality (aHR, 1.27; 95% CI, 1.03-1.57), and severe hypoglycemia (aHR, 1.82; 95% CI, 1.58-2.10), but not with increased risks of ischemic stroke, cardiovascular death, arrhythmia, and heart failure. The duration analyses revealed the highest MACE risk during 1 to 90 days after initiation of mitoKATP channel high-affinity sulfonylureas (aHR, 6.06; 95% CI, 4.86-7.55).Conclusions and Relevance: Use of mitoKATP channel high-affinity sulfonylureas vs low-affinity sulfonylureas was associated with an increased MACE risk in patients with T2D concomitantly receiving metformin, suggesting that high-affinity blockage of the mitoKATP channels could account for sulfonylurea-associated MACEs.
- Open Access
- 14 September 2022
- Published by The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA) in Journal of Food and Drug Analysis
- Vol. 30 (3) , 316-330
Real-world evidence of the herb-drug interactions
Herbal medicine (HM) is a type of medicine that uses active ingredients made from plants to treat diseases and maintain health and wellbeing. Due to its increasing worldwide usage, the possibility of HMs and conventional drugs being concurrently used is high, potentially leading to adverse events resulting from herb-drug interactions. Despite the safety concerns regarding such interactions, few studies have been conducted for assessing clinical consequences of using HMs with conventional drugs in real-world settings. As clinical trials are not forthcoming rapidly enough to provide the evidence for herb-drug interactions, observational studies are considered as an alternative approach. The present review focuses on evaluating the utility of analyzing real-world data in observational research to study the clinical consequences of herb-drug interactions between HMs and conventional drugs. The data sources and study designs of each highlighted literature are examined based on its strengths and limitations in analyzing herb-drug interactions. Finally, future observational studies involving novel and rigorous methodologies that may be effective in studying herb-drug interactions are discussed.
- 14 September 2022
- Published by The Journal of Food and Drug Analysis (JFDA), Food and Drug Administration, Taiwan (TFDA) in Journal of Food and Drug Analysis
- Vol. 30 (3) , 316-330
Open AccessReal-world evidence of the herb-drug interactions
Herbal medicine (HM) is a type of medicine that uses active ingredients made from plants to treat diseases and maintain health and wellbeing. Due to its increasing worldwide usage, the possibility of HMs and conventional drugs being concurrently used is high, potentially leading to adverse events resulting from herb-drug interactions. Despite the safety concerns regarding such interactions, few studies have been conducted for assessing clinical consequences of using HMs with conventional drugs in real-world settings. As clinical trials are not forthcoming rapidly enough to provide the evidence for herb-drug interactions, observational studies are considered as an alternative approach. The present review focuses on evaluating the utility of analyzing real-world data in observational research to study the clinical consequences of herb-drug interactions between HMs and conventional drugs. The data sources and study designs of each highlighted literature are examined based on its strengths and limitations in analyzing herb-drug interactions. Finally, future observational studies involving novel and rigorous methodologies that may be effective in studying herb-drug interactions are discussed.
- 16 March 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (5) , 1276-1287
Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes
OBJECTIVE: Previous studies have revealed an intraclass difference in major adverse cardiovascular events (MACE) among sulfonylureas. In vitro and ex vivo studies reported several sulfonylureas to exhibit high-affinity blockage of cardiac mitochondrial ATP-sensitive potassium (mitoKATP) channels and could interfere with ischemic preconditioning, the most important mechanism of self-cardiac protection. However, no studies have examined whether these varying binding affinities of sulfonylureas could account for their intraclass difference in MACE. We compared mitoKATP channel high-affinity versus low-affinity sulfonylureas regarding the MACE risk in real-world settings. RESEARCH DESIGN AND METHODS: Using the Taiwan nationwide health care claims database, patients with type 2 diabetes initiating sulfonylurea monotherapy between 2007 and 2016 were included in the cohort study. A total of 33,727 new mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylurea users, respectively, were identified after 1:1 propensity score matching. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs) and 95% CI. RESULTS: MitoKATP channel high-affinity sulfonylureas were associated with a significantly increased risk of three-point MACE (aHR 1.21 [95% CI 1.03–1.44]), ischemic stroke (aHR 1.23 [95% CI 1.02–1.50]), and cardiovascular death (aHR 2.61 [95% CI 1.31–5.20]), but not with that of myocardial infarction (aHR 1.04 [95% CI 0.75–1.46]). The duration-response analyses revealed the highest MACE risk to be within 90 days of therapy (aHR 4.67 [95% CI 3.61–6.06]). CONCLUSIONS: Cardiac mitoKATP channel high-affinity sulfonylureas were associated with an increased MACE risk compared with low-affinity sulfonylureas in a nationwide population with diabetes.
- 16 March 2022
- Published by American Diabetes Association in Diabetes Care
- Vol. 45 (5) , 1276-1287
Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes
OBJECTIVE: Previous studies have revealed an intraclass difference in major adverse cardiovascular events (MACE) among sulfonylureas. In vitro and ex vivo studies reported several sulfonylureas to exhibit high-affinity blockage of cardiac mitochondrial ATP-sensitive potassium (mitoKATP) channels and could interfere with ischemic preconditioning, the most important mechanism of self-cardiac protection. However, no studies have examined whether these varying binding affinities of sulfonylureas could account for their intraclass difference in MACE. We compared mitoKATP channel high-affinity versus low-affinity sulfonylureas regarding the MACE risk in real-world settings. RESEARCH DESIGN AND METHODS: Using the Taiwan nationwide health care claims database, patients with type 2 diabetes initiating sulfonylurea monotherapy between 2007 and 2016 were included in the cohort study. A total of 33,727 new mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylurea users, respectively, were identified after 1:1 propensity score matching. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs) and 95% CI. RESULTS: MitoKATP channel high-affinity sulfonylureas were associated with a significantly increased risk of three-point MACE (aHR 1.21 [95% CI 1.03–1.44]), ischemic stroke (aHR 1.23 [95% CI 1.02–1.50]), and cardiovascular death (aHR 2.61 [95% CI 1.31–5.20]), but not with that of myocardial infarction (aHR 1.04 [95% CI 0.75–1.46]). The duration-response analyses revealed the highest MACE risk to be within 90 days of therapy (aHR 4.67 [95% CI 3.61–6.06]). CONCLUSIONS: Cardiac mitoKATP channel high-affinity sulfonylureas were associated with an increased MACE risk compared with low-affinity sulfonylureas in a nationwide population with diabetes.
- Open Access
- 8 January 2022
- Published by Springer Nature in BMC Surgery
- Vol. 22 (1) , 1-8
Navigation-guided nasal endoscopic surgery for acute vision loss caused by fibrous dysplasia: a case report and review of literatures
Background: Bone fibrous dysplasia is a benign disease of bone tissue dysplasia. Vision impairment is the commonest neurological complication of craniofacial fibrous dysplasia. Most of the vision loss caused by craniofacial fibrous dysplasia is usually a gradual process. Very few present with acute visual impairment as described in our case. Case presentation: We report a patient with fibrous dysplasia presenting rapidly progressive visual loss in the left eye secondary to bone cyst formation. Transnasal endoscopic surgery guided by navigation with drainage and curettage of this bone cyst and orbital decompression resulted in progressive improvement in visual acuity that returned to normal 1 month post-operatively. Conclusions: In cases with acute visual loss due to fibrous dysplasia, emergency surgical treatment should be considered to preserve vision. In the surgical approach, navigation-guided nasal endoscopic surgery may be preferred because of its advantages.
- 8 January 2022
- Published by Springer Nature in BMC Surgery
- Vol. 22 (1) , 1-8
Open AccessNavigation-guided nasal endoscopic surgery for acute vision loss caused by fibrous dysplasia: a case report and review of literatures
Background: Bone fibrous dysplasia is a benign disease of bone tissue dysplasia. Vision impairment is the commonest neurological complication of craniofacial fibrous dysplasia. Most of the vision loss caused by craniofacial fibrous dysplasia is usually a gradual process. Very few present with acute visual impairment as described in our case. Case presentation: We report a patient with fibrous dysplasia presenting rapidly progressive visual loss in the left eye secondary to bone cyst formation. Transnasal endoscopic surgery guided by navigation with drainage and curettage of this bone cyst and orbital decompression resulted in progressive improvement in visual acuity that returned to normal 1 month post-operatively. Conclusions: In cases with acute visual loss due to fibrous dysplasia, emergency surgical treatment should be considered to preserve vision. In the surgical approach, navigation-guided nasal endoscopic surgery may be preferred because of its advantages.